Regentis Biomaterials (RGNT) closed its initial public offering of 1.25 million ordinary shares at $8 each for $10 million in gross proceeds, the company said Friday.
The shares began trading Dec. 4 on the NYSE American under the ticker RGNT.
Regentis said it will use the proceeds mainly to advance development of its GelrinC cartilage-repair therapy and for corporate purposes.